Cardiovascular research can feel like a “numbers game” from design and recruitment to analysis. Worldwide brings the experience, decisiveness and tailored solutions your program needs.
Worldwide wins the numbers game. We have more than three decades of experience in cardiovascular research, a presence in more than 60 countries, and extensive global trial experience in all phases of research—even involving more than 26,000 patients in a single trial. Yet every single program receives the attention and care of a dedicated team, enabling us to act quickly and effectively in close collaboration with key industry partners.
President of CVM & Evidence Business Units
Karen Hill, President of CVM & Evidence Business Units, has been with Worldwide Clinical Trials for more than 25 years, providing management and supervision to project managers and CRAs. Karen supervises global teams working on large cardiovascular outcome studies, as well as projects in other cardiovascular indications across all clinical trial phases.
Vice President, General Medicine Medical Lead, Medical Affairs
Vice President Project Management, Cardiovascular
Executive Director, Scientific Solutions, Cardiovascular, Endocrine & Metabolic
Senior Director, Project Management
Cardiovascular trials often require teamwide dedication to a broad scope and a patient, detail-oriented operational approach. At Worldwide, we believe each study relies on the commitment of the individuals involved. Find out how this comes through in everything we do.
Our experience executing large cardiovascular trials has resulted in irreplaceable expertise: a solid understanding of the events, treatment, and outcomes of interest. These studies require event adjudication and close collaboration with Clinical Events Committees (CECs).
Worldwide can do more than screen patients for inclusion and exclusion criteria. Using emerging predictive analytics technology, we identify the study subjects most likely to comply with the protocol and stay the course of the trial.
Smart screening and high compliance rates reduce enrollment costs. Paired with thoughtful statistical analysis plans and early leading signals for rapid identification of struggling products, we offer shorter trials for patients and faster decision-making guidance for sponsors.
Worldwide minimizes attrition and improves statistical validity by anticipating the pain points most likely to cause attrition. We then proactively work to alleviate those concerns, honoring patients’ time and commitment through compressed timelines and reduced study burden.